Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- primary
研究概览
简要总结
- To assess staging accuracy of F-18 FDG PET/CT in lymphoma
- Determine the role of F-18 FDG PET/CT in monitoring treatment response and detecting relapse or residual disease in lymphoma
- To evaluate FDG uptake correlation with histopathological subtypes and immunophenotypes as a prognostic factor.
详细描述
The incidence of lymphoma in Egypt has been increasing in recent years, with a noticeable rise in both Hodgkin's and non-Hodgkin's lymphoma cases. This increase is due to better healthcare, awareness, and diagnostic advancements. Risk factors include infections, lifestyle, genetics, and immune system issues.
Lymphoma is now the fourth most prevalent cancer among Egyptian adults, accounting for approximately 8.4% of all new cancer cases annually. As the burden of lymphoma grows, it becomes essential to develop effective strategies for its diagnosis and management.
Flurodeoxyglucose F-18 (F-18 FDG) is a radiolabeled glucose analog that accumulates in metabolically active cells, such as lymphoma cells, making F-18 FDG positron emission tomography / computed tomography scan (PET/CT) highly sensitive for detecting malignant lesions. It plays a key role in staging lymphoma by assessing the extent of disease spread.
Additionally, F-18 FDG PET/CT is essential for assessing treatment response, detecting relapses early, and evaluating the prognosis of patients, offering prognostic value by evaluating residual disease and predicting recurrence. Its ability to monitor disease progression and detect recurrent lymphoma provides critical insights that guide therapeutic decisions and long-term outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: Patient must be older than 18 years.
- •Confirmed Diagnosis of Lymphoma: Patient must have a confirmed diagnosis of lymphoma based on histopathology and immunophenotyping.
排除标准
- •Patients with Known concomitant malignancy.
- •Pregnancy: Pregnant women due to the potential risks associated with radiation exposure from the PET/CT scan.
- •Severe Renal or Hepatic Impairment: Patients with significant renal or hepatic dysfunction that could affect FDG metabolism or excretion.
- •Uncontrolled Diabetes: Patients with uncontrolled diabetes (blood glucose >200 mg/dL), as it can affect FDG uptake and PET/CT results.
结局指标
主要结局
primary
时间窗: 3 years
Treatment Response Using Deauville Score for FDG Uptake Evaluation: Evaluate FDG uptake using the 5-point scale: 1. No uptake above background 2. Uptake ≤ mediastinum 3. Uptake \> mediastinum but ≤ liver 4. Moderately increased compared to liver 5. Markedly increased compared to liver X: New uptake, unlikely related to lymphoma
次要结局
- secondary(3 years)
研究者
Aya Abdel-Baset Ahmed Ali Alsanory
Assisstant lecturer
Assiut University